A new approach to treat Alzheimer’s disease

Alzheimer; News from the web:

A new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline

The ACT-AD and LIFT-AD trials are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease.

The investigational drug of the ACT-AD and LIFT-AD trials is designed to:

  • Boost a repair and regenerative pathway for brain cells
  • Promote brain health and function

There may be a trial near you check it out

Read all about it HERE

A safer Alzheimer’s drug

Alzheimer; News from the web:

In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.

Read all about it HERE

A Vaccine for Alzheimer’s Disease?

Alzheimer; News from the web:

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

https://www.technologynetworks.com/

Read all about it HERE

FDA does not approve new Alzheimer’s drug

Alzheimer; News from the web:

Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.

The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.

Read all about it HERE